Heterocyclic NMDA antagonists
US11834409B2 · kind B2 · utility
0Cited by
2References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2022 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Dec 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.